Abstract: The present invention relates to an in vitro method of determining the need of a patient being diagnosed for, suffering from or being at risk of developing cancer, for a given therapy, the method comprising determining, in vitro, in one or more samples collected from said patient, the activity of at least one enzyme selected from the group consisting of Tryptophan Hydroxylase, 5-HTP decarboxylase, Arginase and/or Nitric oxide synthase (NOS), and determining the patient to be in need of a combined treatment comprising anti-cancer therapy, and an inhibitor of Tryptophan Hydroxylase, 5-HTP decarboxylase, Arginase and/or Nitric oxide synthase (NOS) if a high activity of the respective enzyme is determined in step a), while determining the patient to be in need of a cancer treatment comprising anti-cancer therapy, if a low activity of the respective enzyme is determined in step a) (FIG. 5).

Abstract: The present invention telates to a method for detecting small molecular analytes in a sample, which method comprises derivatizing at least one small molecular analyte or at least one carrier molecule, in such way that one can bind to the other, thus forming at least one analyte-carrier complex, adding a detection immunoligand that s binds to the analyte-carrier complex, and detecting the small molecular analyte.

Abstract: The present invention relates to a method of predicting the therapeutic efficacy of at least one therapy approach in the treatment of a neoplastic disease in a patient. The method comprises the following steps: a) Determining the presence or concentration of at least one enzyme or metabolite of the Kynurenine pathway in a patient sample, and b) Concluding, from step a), whether the at least one therapy approach will be therapeutically effective in the treatment of the neoplastic disease.

Abstract: The present invention telates to a method for detecting small molecular analytes in a sample, which method comprises derivatizing at least one small molecular analyte or at least one carrier molecule, in such way that one can bind to the other, thus forming at least one analyte-carrier complex, adding a detection immunoligand that s binds to the analyte-carrier complex, and detecting the small molecular analyte.

Abstract: The present invention relates to a modulator of an enzyme and/or a metabolite of the kynurenine pathway (FIG. 18).